Abstract
Background: The function of microRNA-542-3p (miR-542-3p) in rat epilepsy is still unclear.
Methods: The levels of miR-542-3p and toll-like receptor 4 (TLR4) were determined through quantitative real-time PCR. The protein levels were examined via the western blot analysis. The relationship between miR-542-3p and TLR4 was confirmed through luciferase assay. Pathological changes were analyzed via Hematoxylin-eosin (HE) and Nissl staining.
Results: The rats and hippocampal cells were treated with kainic acid (KA) in vivo and in vitro. miR-542-3p was low in KA-treated rats, hippocampal cells and cerebrospinal fluid of patients with epilepsy. Further functional analysis showed that miR-542-3p overexpression inhibited KAinduced average seizure frequency, damage of hippocampal neuron and cell apoptosis, leading to the alleviation of the brain injury in epilepsy rats. miR-542-3p was determined to downregulate TLR4 expression. The relationship between miR-542-3p and TLR4 was confirmed. TLR4 knockdown reduced KA-induced nuclear factor-kappa B p65 (NF-κB p65), multidrug resistance 1 (MDR1), P-glycoprotein (P-gp) and apoptosis-associated protein levels. Further, for NF-κB p65, MDR1, P-gp and apoptosis-associated protein levels detection, miR-542-3p mimic showed a suppressive effect on these KA-induced protein levels, whereas TLR4 overexpression ameliorated the miR-542-3p-induced these protein levels in KA-treated epilepsy rats.
Conclusion: We identified that miR-542-3p attenuated seizure-induced brain injury and the expression of P-gp in epilepsy rats through inhibiting TLR4/NF-κB signaling pathway, which might contribute to improved epilepsy therapy.
Keywords: miR-542-3p, TLR4, NF-κB, P-gp, epilepsy, hematoxylin-eosin.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03121.x] [PMID: 21899536]
[http://dx.doi.org/10.1586/ern.12.129] [PMID: 23237349]
[http://dx.doi.org/10.3389/fncel.2019.00180] [PMID: 31114485]
[http://dx.doi.org/10.1016/0306-4522(85)90299-4] [PMID: 2859548]
[http://dx.doi.org/10.1038/sj.jcbfm.9600149] [PMID: 15889042]
[http://dx.doi.org/10.1002/(SICI)1096-9861(19990222)404:4<537:AID-CNE9>3.0.CO;2-#] [PMID: 9987996]
[http://dx.doi.org/10.1111/j.1528-1167.2007.00992.x] [PMID: 17316406]
[http://dx.doi.org/10.1111/j.1528-1167.2011.03024.x] [PMID: 21426333]
[http://dx.doi.org/10.1212/WNL.0b013e3182563b19] [PMID: 22573629]
[http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]
[http://dx.doi.org/10.1097/CMR.0b013e32834f6fbb] [PMID: 22209751]
[http://dx.doi.org/10.2174/138920209788185252] [PMID: 19881909]
[http://dx.doi.org/10.1371/journal.pone.0006121] [PMID: 19568434]
[http://dx.doi.org/10.1007/s00702-014-1338-4] [PMID: 25395183]
[http://dx.doi.org/10.1016/j.neulet.2010.11.040] [PMID: 21094214]
[http://dx.doi.org/10.1016/j.brainres.2011.12.001] [PMID: 22197703]
[http://dx.doi.org/10.1016/j.expneurol.2012.06.029] [PMID: 22771761]
[http://dx.doi.org/10.1186/1471-2202-13-115] [PMID: 22998082]
[http://dx.doi.org/10.1371/journal.pone.0024370] [PMID: 21931695]
[http://dx.doi.org/10.1101/cshperspect.a000034] [PMID: 20066092]
[http://dx.doi.org/10.1016/j.phymed.2008.10.008] [PMID: 19103478]
[http://dx.doi.org/10.3892/mmr.2018.8485] [PMID: 29393419]
[http://dx.doi.org/10.1016/j.brainresbull.2017.05.004] [PMID: 28528202]
[http://dx.doi.org/10.1021/bi982236+] [PMID: 10026303]
[http://dx.doi.org/10.1038/sj.onc.1206056] [PMID: 12527911]
[http://dx.doi.org/10.1016/j.nbd.2006.06.014] [PMID: 16928449]
[http://dx.doi.org/10.1007/s00018-013-1397-y] [PMID: 23771630]
[http://dx.doi.org/10.1038/mt.2014.113]
[http://dx.doi.org/10.3389/fncel.2019.00145] [PMID: 31031600]
[http://dx.doi.org/10.1186/s12935-019-0821-2] [PMID: 31049031]
[http://dx.doi.org/10.1111/cns.12991] [PMID: 29808547]
[PMID: 29883722]
[PMID: 30799593]
[PMID: 31061316]
[PMID: 30210283]